TRIO Score and Choosing Patients Most Likely to Benefit From Tricuspid Valve Intervention

Mayo Clinic Cardiovascular CME

TRIO Score and Choosing Patients Most Likely to Benefit From Tricuspid Valve Intervention
Guest: Sorin V. Pislaru, M.D., Ph.D.

Hosts: Sharonne N. Hayes, M.D.
Tricuspid Regurgitation (TR) is an extraordinarily heterogeneous, highly prevalent valvular heart disease. Given the tremendous variability, individualizing risk in patients with TR to guide appropriate therapy will be explored. Other topics discussed will be the use of TRIO scores, GDMT as a first line in therapy, as well as when to consider surgery or percutaneous interventions.

Topics Discussed:

• Is TR a relevant valvular heart disease?
• Why the need for a risk score?
• So what is the TRIO score
• What else did you learn from the score?
• The future?

Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices.

LinkedIn: Mayo Clinic Cardiovascular Services

Cardiovascular Education App:
The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today!
No CME credit offered for this episode.

Podcast episode transcript found here.